1-7 of 7
Max Wolf, MBBS FRACP
Close
Sort by
Journal Articles

Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after Four Cycles of R-CHOP-14: A Multicenter Phase II Study of the Australasian Leukaemia Lymphoma Study Group (ALLG)

Mark S Hertzberg, MBBS PhDFRACP FRCPA, Maher K Gandhi, PhDFRACP FRCPath FRCP, Belinda Butcher, BSc MBiostat PhDCMPP, Ruth Columbus, BSc PhD, John Taper, MBBS FRACP FRCPA, Judith Trotman, MBChB, Devinder Gill, MB FRCPath FRACP FRCPA, Shir-Jing Ho, MBBS FRACP FRCPA, Keith Fay, MBChB FRACP FRCPA, Gavin Cull, MBBS DM FRACP FRCPA, Andrew P Grigg, MBBS MD, Geoff Chong, MBBS FRACP, Ian D. Lewis, MBBS PhDFRACP FRCPA, Sam Milliken, MBBS FRACP FRCPA, William Renwick, Uwe Hahn, MBBS FRACP FRCPA, Robin Filshie, PhDFRACP FRCPA, Anne-Marie Watson, MBBS FRACP FRCPA, George Kannourakis, MD PhD, Max Wolf, MBBS FRACP FRCPA, Andrew Wirth, MBBS, Pauline Therese Warburton, MBBS PhDFRACP FRCPA, Stephen Robert Larsen, MBBS PhDFRCPA FRACP, John F. Seymour, MBBS, PhD, Rodney Hicks, MBBS FRACP
Journal: Blood
Blood (2015) 126 (23): 815.
https://doi.org/10.1182/blood.V126.23.815.815
Published: 2015
Journal Articles

Incorporating High-Dose IV Methotrexate Into Initial Therapy Results In Lower Rates Of Central Nervous System (CNS) Relapse In Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Chan Y Cheah, MBBS, FRACP, FRCPA, Kirsten Herbert, MD, BSci(Med), FRACP, PhD, Kacey O'Rourke, MBBS FRACP FRCPA, Glen Kennedy, MBBS FRACP FRCPA, Anupkumar George, MBBS FRACP FRCPA, Pasquale Fedele, MBBS, Shuh Ying Tan, MBBS, Stephen Opat, MBBS(Hons) FRACP FRCPA, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Max Wolf, MBBS, FRACP, FRCPA, Elchanan H. Januszewicz, MBBS FRACP FRCPA, Michael J. Dickinson, MBBS, FRACP, FRCPA, David A Westerman, MBBS, FRACP, FRCPA, H. Miles Prince, MBBS, FRACP, FRCPA, MD, Dennis A Carney, MBBS FRACP FRCPA, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Constantine S. Tam, MBBS, FRACP, FRCPA, MD, John F Seymour, MBBS, PhD, FRACP
Journal: Blood
Blood (2013) 122 (21): 4353.
https://doi.org/10.1182/blood.V122.21.4353.4353
Published: 2013
Journal Articles

Lack Of Benefit From Surveillance PET-CT In Transformed Indolent Lymphoma (TrIL) In Complete Metabolic Remission (CMR) Following Therapy

Chan Y Cheah, MBBS, FRACP, FRCPA, Michael J. Dickinson, MBBS, FRACP, FRCPA, Anupkumar George, MBBS FRACP FRCPA, Michael S Hofman, MBBS FRACP FAANMS, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, David Ritchie, MBBS, FRACP, FRCPA, PhD, H Miles Prince, MB, BS, FRACP, FRCPA, MRACMA, MD, Kirsten Herbert, MD, BSci(Med), FRACP, PhD, Max Wolf, MBBS, FRACP, FRCPA, Elchanan H. Januszewicz, MBBS FRACP FRCPA, Dennis A Carney, MBBS FRACP FRCPA, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Constantine S Tam, MBBS, FRACP, FRCPA, MD, John F. Seymour, MBBS, FRACP, PhD
Journal: Blood
Blood (2013) 122 (21): 1796.
https://doi.org/10.1182/blood.V122.21.1796.1796
Published: 2013
Journal Articles

Surveillance PET-CT Scanning Is Useful in the First 18 Months Following Completion of Therapy for Patients with Diffuse Large B-Cell Lymphoma with IPI≥3.

Chan Y Cheah, MBBS, FRACP, FRCPA, Michael S Hofman, MBBS FRACP, Michael J. Dickinson, MBBS, FRACP, FRCPA, Andrew Wirth, MBBS, FRANZCR, David A Westerman, MBBS, FRACP, FRCPA, FFSc, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Max Wolf, MBBS, FRACP, FRCPA, Elchanan H. Januszewicz, MBBS FRACP FRCPA, Kirsten Herbert, MD, BSci(Med), FRACP, PhD, Miles Prince, MD, FRACP, FRCPA, Dennis A Carney, MBBS FRACP FRCPA, David Ritchie, MBBS, FRACP, FRCPA, PhD, Rodney Hicks, MB BS, MD, FRACP, John F Seymour, MB, BS, PhD, FRACP
Journal: Blood
Blood (2012) 120 (21): 2652.
https://doi.org/10.1182/blood.V120.21.2652.2652
Published: 2012
Journal Articles

CNS Disease In Younger Patients (<=60 years) with Aggressive Lymphoma Treated In Trials of the German High Grade Non Hodgkin Lymphoma Study Group (DSHNHL) and the MabThera International Trial (MInT)

Norbert Schmitz, MD, Samira Zeynalova, Bertram Glass, MD, Ulrich Kaiser, MD, Eva Cavallin-Stahl, MD, Max Wolf, MBBS, FRACP, FRCPA, Mathias Haenel, MD, Markus Loeffler, MD, Lorenz Trümper, MD, M. Pfreundschuh
Journal: Blood
Blood (2010) 116 (21): 112.
https://doi.org/10.1182/blood.V116.21.112.112
Published: 2010
Journal Articles

The Addition of Systemic High-Dose Methotrexate (HD-MTX) to Intrathecal Chemotherapy (IT) for Central Nervous System (CNS) Prophylaxis Substantilly Reduces CNS Recurrence Rates in Patients with at-Risk Aggressive Lymphoma: A Historically Controlled Prospective Study

Kirsten Herbert, MBBS, FRACP, PhD, Max Wolf, MBBS, FRACP, FRCPA, Dennis Carney, MBBS, FRACP, FRCPA, David Alan Westerman, MBBS, FRACP, FRCPA, Henry Januszewicz, MBBS, FRACP, FRCPA, Simon Harrison, MBBS, PhD, David Ritchie, MBChB, FRACP, FRCPA, PhD, H. Miles Prince, John Francis Seymour, MBBS, FRACP, PhD
Journal: Blood
Blood (2008) 112 (11): 3596.
https://doi.org/10.1182/blood.V112.11.3596.3596
Published: 2008
Journal Articles

Relapse Following Chemotherapy in Aggressive Non-Hodgkin’s Lymphoma Occurs Frequently in Original Sites of Disease.

Max Wolf, MBBS FRACP, Susan J. Morgan, MBBS FRACP FRCPA, Andrew Wirth, MBBS FRACP FRANZCR, John Reynolds, PhD, Janey Stone, MSc, Miles Prince, MBBS FRACP FRCPA MD
Journal: Blood
Blood (2004) 104 (11): 4587.
https://doi.org/10.1182/blood.V104.11.4587.4587
Published: 2004